MR-proANP and MR-proADM for risk stratification of patients with acute chest pain

Heart

Volumn 99, Issue 6, 2013, Pages 388-395

  Tzikas, Stergios ^a   Keller, Till ^b   Ojeda, Francisco M ^c   Zeller, Tanja ^c   Wild, Philipp S ^a   Lubos, Edith ^c   Kunde, Jan ^d   Baldus, Stephan ^c,e   Bickel, Christoph ^f   Lackner, Karl J ^a   Münzel, Thomas F ^a   Blankenberg, Stefan ^c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d BRAHMS GmbH   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; THORAX PAIN;

ACUTE DISEASE; ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CHEST PAIN; FOLLOW-UP STUDIES; GERMANY; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84874192198     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302956     Document Type: Article

References (33)

1. Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
2. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949-52. (Pubitemid 46328287)
3. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A-and B-type natriuretic peptides. Clin Chem 2004;50:1576-88. (Pubitemid 39121226)
4. Morgenthaler NG, Struck J, Thomas B, et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-6. (Pubitemid 38125732)
5. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
6. Miller WL, Hartman KA, Grill DE, et al. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 2012;98:389-94.
7. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
8. Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Tech 2002;57:3-13. (Pubitemid 34242539)
9. Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823-9. (Pubitemid 41368172)
10. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-10. (Pubitemid 46659061)
11. Wild PS, Schnabel RB, Lubos E, et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the Athero Gene study. Clin Chem 2012;58:226-36.
12. Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010;12:338-47.
13. Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.
14. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096-106.
15. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Alpert JS, White HD, et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007;28:2525-38.
16. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-72. (Pubitemid 46580250)
17. Keller T, Ojeda F, Zeller T, et al. Defining a reference population to determine the 99th percentile of a contemporary sensitive cardiac troponin I assay. Int J Cardiol 2012; [Epub ahead of print, 4 May 2012].
18. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999;99:1165-72. (Pubitemid 29120088)
19. Michael JP, Ralph BDA, Ewout WS. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
20. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
21. Meune C, Twerenbold R, Drexler B, et al. Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction. Am J Cardiol 2012;109:1117-23.
22. Dhillon OS, Khan SQ, Narayan HK, et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol 2010;56:125-33.
23. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. New Engl J Med 2009;360:2165-75.
24. von Haehling S, Papassotiriou J, Hartmann O, et al. Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease. Clin Sci 2012;123:601-10.
25. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Euro Heart J 2012;33:2001-6.
26. Khan SQ, Dhillon O, Kelly D, et al. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2008;51:1857-64. (Pubitemid 351615250)
27. Khan SQ, O'Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007;49:1525-32. (Pubitemid 46517963)
28. Maisel A, Mueller C, Nowak RM, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011;58:1057-67.
29. von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010;12:484-91.
30. Shah RV, Truong QA, Gaggin HK, et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart 2012;33:2197-205.
31. Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45. (Pubitemid 34833157)
32. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-39.
33. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-33. (Pubitemid 38725422)